A Phase 1 TH-302 Mass Balance Trial

Solid Tumor Clinical Trial

Official title:

A Phase I, Open-Label, Two-Center Trial to Investigate the Mass Balance and Metabolite Profile of TH-302 in Cancer Patients With Locally Advanced or Metastatic Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02076230
• Other study ID #: EMR200592-007
• Secondary ID: 2013-003950-25
• Status: Completed
• Phase: Phase 1
• First received: February 20, 2014
• Last updated: June 9, 2016
• Start date: February 2014
• Est. completion date: March 2016

Study information

• Verified date: June 2016
• Source: Merck KGaA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, Phase 1, two-center trial to evaluate the mass balance and metabolite profile of carbon 14 [14C]-labeled TH-302 (Label 1 and Label 2) followed by subsequent treatment with unlabeled TH-302 in cancer subjects with locally advanced or metastatic solid tumors.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: March 2016
• Est. primary completion date: September 2014
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Male subject with pathologically or cytologically confirmed solid tumor which is locally advanced or metastatic, and either refractory to the standard therapy or for which no effective standard therapy is available

• Subject has measurable and evaluable disease as RECIST version 1.1

• Age greater than or equal to (>=) 18 years and less than or equal to (=<) 70 years

• Body mass index (BMI) >= 19 and =< 33 kilogram per square meter (kg/m^2), body weight greater than (>) 50 kilogram (kg)

• Eastern cooperative oncology group (ECOG) performance status of 0 to 1

• Life expectancy of at least 3 months

• At least 4 weeks from previous cytotoxic chemotherapy or radiation therapy and at least 5 half-lives or 6 weeks, whichever is longer, after targeted or biologic therapy

• Acceptable renal function, liver function and hematologic status as defined in the protocol

• Other protocol-defined inclusion criteria could apply

Exclusion Criteria:

• New York Heart Association (NYHA) Class 3 or 4 congestive heart disease, myocardial infarction within 6 months, unstable arrhythmia, symptomatic ischemic heart disease or symptomatic peripheral arterial vascular disease

• Severe chronic obstructive or other pulmonary disease with hypoxemia as defined in the protocol

• Major surgery, other than diagnostic surgery, =< 28 days prior to Day 1. Subject must have completely recovered from surgery

• Primary brain tumors or clinical evidence of active brain metastasis as defined in the protocol

• Treatment with strong inhibitors and/or inducers of drug metabolic enzymes or drug transporter as defined in the protocol

• Participation in a drug trial within 30 days prior to start of trial medication. Participation in a trial involving administration of 14C-labeled compound(s) within last 6 months prior to start of study drug

• Inability to understand the protocol requirements, instructions and trial-related restrictions, the nature, scope, and possible consequences of the trial

• Legal incapacity or limited legal capacity

• Other protocol-defined exclusion criteria could apply

Related Conditions & MeSH terms

• Solid Tumor

Intervention

Drug:
• [14C] TH-302 (Label 1)
[14C]-labeled TH-302 (Label 1) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
• [14C] TH-302 (Label 2)
[14C]-labeled TH-302 (Label 2) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
• Unlabeled TH-302
Unlabeled TH-302 will be administered along with labeled TH-302 at the dose of 340 milligram per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1 of Part A, followed by recommended Phase 2 dose (RP2D) of 480 mg/m^2 as monotherapy infusion over 30 minutes on Days 8 and 15 of Part A; and on Days 1, 8 and 15 of Part B, until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow up, or death.

Locations

Country	Name	City	State
Germany	Please contact the Merck KGaA Communication Center located in	Darmstadt

Sponsors (2)

Lead Sponsor	Collaborator
Merck KGaA	Threshold Pharmaceuticals

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics profile in plasma: Cmax, Tmax, AUC (0-t), lambda_z, t1/2, AUC (0-infinity), CL, Vss, Vz, MRT for TH-302 and its active metabolite Br-IPM		Days 1 and 8 of Cycle 1
Primary	Pharmacokinetics profile in excreta: Cumulative Ae (0-t), Ae (0-infinity), percent radioactive dose excreted in urine and feces, AeUF, CLR, CLNR for TH-302 and its active metabolite Br-IPM		Day 1 of Cycle 1
Secondary	Number of subjects with Treatment-emergent adverse events (TEAEs)		Baseline up to Day 30 after the last dose of study treatment
Secondary	Blood to plasma ratio of total 14C-radioactivity		Days 1 and 8 of Cycle 1
Secondary	Total and free plasma concentrations of TH-302 in plasma		Day 1 of Cycle 1
Secondary	Number of subjects with tumor response according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)	Tumor response was defined as the occurrence of complete response (CR) or partial response (PR) based on the investigator's assessment according to RECIST v 1.1.	Up to 1 year
Secondary	Unbound fraction (fu) of TH-302 in plasma		Day 1 of Cycle 1